Mark Ragosa - 09 Mar 2026 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Douglas Barry, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
09 Mar 2026
Net transactions value
-$1,686,158
Form type
4
Filing time
11 Mar 2026, 16:38:02 UTC
Previous filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ragosa Mark CHIEF FINANCIAL OFFICER C/O KINIKSA PHARMACEUTICALS INT'L, PLC, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM /s/ Douglas Barry, Attorney-in-Fact 11 Mar 2026 0001835458

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +2,036 +17% $22.89* 14,122 09 Mar 2026 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise +10,513 +74% $17.76* 24,635 09 Mar 2026 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise +13,813 +56% $18.06* 38,448 09 Mar 2026 Direct F1
transaction KNSA Class A Ordinary Share Options Exercise +10,360 +27% $26.74* 48,808 09 Mar 2026 Direct F1
transaction KNSA Class A Ordinary Share Sale $819,574 -17,981 -37% $45.58 30,827 09 Mar 2026 Direct F1, F2
transaction KNSA Class A Ordinary Share Sale $866,584 -18,741 -61% $46.24 12,086 09 Mar 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise -2,036 -100% $0.000000* 0 09 Mar 2026 Class A Ordinary Share 2,036 $22.89 Direct F1, F4
transaction KNSA Share Option Options Exercise -10,513 -36% $0.000000* 18,396 09 Mar 2026 Class A Ordinary Share 10,513 $17.76 Direct F1, F5
transaction KNSA Share Option Options Exercise -13,813 -42% $0.000000* 19,337 09 Mar 2026 Class A Ordinary Share 13,813 $18.06 Direct F1, F6
transaction KNSA Share Option Options Exercise -10,360 -31% $0.000000* 22,790 09 Mar 2026 Class A Ordinary Share 10,360 $26.74 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.885 and $45.88. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.89 and $46.79. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.
F4 The option is fully vested and exercisable.
F5 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
F6 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
F7 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024.